Skip to main content
. 2012 Jul 20;97(10):E2006–E2015. doi: 10.1210/jc.2012-1903

Fig. 5.

Fig. 5.

Runx2 expression in human metastatic PTC. A–D, Immunohistochemistry staining of Runx2 (brown) in four representative metastatic PTC, with hematoxylin (blue). Magnification, ×40. The insets (a–d) show higher magnification of the same field. Magnification, ×200. Runx2 staining is confined to nuclei and clearly visible in tumor cells. E–L, Immunohistochemistry staining of Runx2 (brown) in three representative metastatic PTC (E, F, and G) and corresponding lymph node metastases (H, I, and L), with hematoxylin (blue). Magnification, ×200. Runx2 is strongly expressed in human thyroid carcinoma cells both at the primary and metastatic site. M, Semiquantitative RT-PCR of Runx2 isoform expression in three human metastatic PTC (PTC1, PTC2, and PTC3). GAPDH expression was used as control for the amount of starting RNA used for the analysis. M, Molecular weight marker. N, Deoxyribonuclease sensitivity assay of the P1 and P2 Runx2 promoters in Id1A, Id1B, and control cells (ct3). Chromatin accessibility is expressed as a percentage on a scale ranging from a constitutively expressed gene (GAPDH) to a constitutively repressed gene (rhodopsin).